Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: Implications for vaccine design

Journal of Immunology

Volumn 174, Issue 8, 2005, Pages 4812-4820

  Borbulevych, Oleg Y ^a   Baxter, Tiffany K ^a   Yu, Zhiya ^b   Restifo, Nicholas P ^b   Baker, Brian M ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HYDROGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHIONINE; PEPTIDE; THREONINE; TUMOR ANTIGEN; VACCINE;

AMINO ACID SUBSTITUTION; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; BLOOD; CONTROLLED STUDY; CRYSTALLOGRAPHY; DISSOCIATION; DRUG DESIGN; DRUG STABILITY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; T LYMPHOCYTE; TEMPERATURE; THERMODYNAMICS;

EID: 17044415359     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.8.4812     Document Type: Article

References (49)

1. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:187.
2. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
3. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553.
4. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529.
5. Parkhurst, M., M. Salgaller, S. Southwood, P. Robbins, A. Sette, S. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201- binding residues. J. Immunol. 157:2539.
6. Kersh, G. J., M. J. Miley, C. A. Nelson, A. Grakoui, S. Horvath, D. L. Donermeyer, J. Kappler, P. M. Allen, and D. H. Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166:3345.
7. Sharma, A. K., J. J. Kuhns, S. Yan, R. H. Friedline, B. Long, R. Tisch, and E. J. Collins. 2001. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J. Biol. Chem. 276:21443.
8. Baker, B. M., S. J. Gagnon, W. E. Biddison, and D. C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/ MHC interface: implications for TCR signaling. Immunity 13:475.
9. Hemmer, B., I. Stefanova, M. Vergelli, R. N. Germain, and R. Martin. 1998. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J. Immunol. 160:5807.
10. Yu, Z., M. R. Theoret, C. E. Touloukian, D. R. Surman, S. C. Garman, L. Feigenbaum, T. K. Baxter, B. M. Baker, and N. P. Restifo. 2004. Poor immunogenicity of a self/tumor antigen derives from peptide/MHC-I instability and is independent of tolerance. J. Clin. Invest. 114:551.
11. Irvine, K. R., M. R. Parkhurst, E. P. Shulman, J. P. Tupesis, M. Custer, C. E. Touloukian, P. F. Robbins, A. G. Yafal, P. Greenhalgh, R. P. M. Sutmuller, et al. 1999. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res. 59:2536.
12. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, S. L. Topalian, R. M. Sherry, N. P. Restifo, J. R. Wunderlich, C. A. Seipp, L. Rogers-Freezer, et al. 2003. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9:2973.
13. Garboczi, D. N., D. T. Hung, and D. C. Wiley. 1992. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA 89:3429.
14. Otwinowski, Z., and W. Minor. 1997. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307.
15. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760.
16. Bouvier, M., H. C. Guo, K. J. Smith, and D. C. Wiley. 1998. Crystal structures of HLA-A*0201 complexed with antigenic peptides with either the amino- or carboxyl-terminal group substituted by a methyl group. Proteins 33:97.
17. Murshudov, G., A. Vagin, and E. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D. Biol. Crystallogr. 53:240.
18. Morris, R. J., A. Perrakis, and V. S. Lamzin. 2003. ARP/wARP and automatic interpretation of protein electron density maps. Macromolec. Crystallogr. D. 374:229.
19. McRee, D. E. 1999. XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:156.
20. Laskowski, R. A., M. W. Macarthur, D. S. Moss, and J. M. Thornton. 1993. Procheck - a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283.
21. Rodriguez, R., G. Chinea, N. Lopez, T. Pons, and G. Vriend. 1998. Homology modeling, model and software evaluation: three related resources. Bioinformatics 14:523.
22. Laskowski, R. A. 1995. Surfnet - a program for visualizing molecular-surfaces, cavities, and intermolecular interactions. J. Mol. Graphics 13:323.
23. Binz, A. K., R. C. Rodriguez, W. E. Biddison, and B. M. Baker. 2003. Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer. Biochemistry 42:4954.
24. Bevington, P. R., and D. K. Robinson. 1992. Data Reduction and Error Analysis for the Physical Sciences. McGraw-Hill, New York.
25. Madden, D. R., D. N. Garboczi, and D. C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. [Published erratum appears in 1994 Cell 76:following 410.] Cell 75:693.
26. Khan, A. R., B. M. Baker, P. Ghosh, W. E. Biddison, and D. C. Wiley. 2000. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J. Immunol. 164:6398.
27. Wang, Z., R. Turner, B. M. Baker, and W. E. Biddison. 2002. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors. J. Immunol. 169:3146.
28. + CTL. J. Immunol. 171:2233.
29. Collins, E. J., D. N. Garboczi, and D. C. Wiley. 1994. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 371:626.
30. Gao, G. F., J. Tormo, U. C. Gerth, J. R. Wyer, A. J. McMichael, D. I. Stuart, J. I. Bell, E. Y. Jones, and B. K. Jakobsen. 1997. Crystal structure of the complex between human CD8α(α) and HLA-A2. Nature 387:630.
31. Hillig, R. C., P. G. Coulie, V. Stroobant, W. Saenger, A. Ziegler, and M. Hulsmeyer. 2001. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J. Mol. Biol. 310:1167.
32. Kirksey, T. J., R. R. Pogue-Caley, J. A. Frelinger, and E. J. Collins. 1999. The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes. J. Biol. Chem. 274:37259.
33. Kuhns, J. J., M. A. Batalia, S. Yan, and E. J. Collins. 1999. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J. Biol. Chem. 274:36422.
34. Sliz, P., O. Michielin, J.-C. Cerottini, I. Luescher, P. Romero, M. Karplus, and D. C. Wiley. 2001. Crystal structures of two closely related but anligenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J. Immunol. 167:3276.
35. Zhao, R., D. J. Loftus, E. Appella, and E. J. Collins. 1999. Structural evidence of T cell xeno-reactivity in the absence of molecular mimicry. J. Exp. Med. 189:359.
36. Reid, S. W., S. McAdam, K. J. Smith, P. Klenerman, C. A. O'Callaghan, K. Harlos, B. K. Jakobsen, A. J. McMichael, J. I. Bell, D. I. Stuart, and E. Y. Jones. 1996. Antagonist HIV-1 gag peptides induce structural changes in HLA B8. J. Exp. Med. 184:2279.
37. Lee, J. K., G. Stewart-Jones, T. Dong, K. Harlos, K. Di Gleria, L. Dorrell, D. C. Douek, P. A. van der Merwe, E. Y. Jones, and A. J. McMichael. 2004. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200:1455.
38. Webb, A. I., M. A. Dunstone, W. Chen, M.-I. Aguilar, Q. Chen, H. Jackson, L. Chang, L. Kjer-Nielsen, T. Beddoe, J. McCluskey, et al. 2004. Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J. Biol. Chem. 279:23438.
39. Ding, Y. H., B. M. Baker, D. N. Garboczi, W. E. Biddison, and D. C. Wiley. 1999. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11:45.
40. Eriksson, A. E., W. A. Baase, X. J. Zhang, D. W. Heinz, M. Blaber, E. P. Baldwin, and B. W. Matthews. 1992. Response of a protein-structure to cavity-creating mutations and its relation to the hydrophobic effect. Science 255:178.
41. Baxter, T. K., S. J. Gagnon, R. L. Davis-Harrison, J. C. Beck, A.-K. Binz, R. V. Turner, W. E. Biddison, and B. M. Baker. 2004. Strategic mutations in the class I MHC HLA-A2 independently affect both peptide binding and T cell receptor recognition. J. Biol. Chem. 279:29175.
42. b complex. Biochemistry 38:12165.
43. Gakamsky, D. M., D. M. Davis, J. L. Strominger, and I. Pecht. 2000. Assembly and dissociation of human leukocyte antigen (HLA)-A2 studied by real-time fluorescence resonance energy transfer. Biochemistry 39:11163.
44. 209-217-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162:1749.
45. Denkberg, G., E. Klechevsky, and Y. Reiter. 2002. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J. Immunol. 169:4399.
46. Biddison, W. E., R. V. Turner, S. J. Gagnon, A. Lev, C. J. Cohen, and Y. Reiter. 2003. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J. Immunol. 171:3064.
47. Cornette, J. L., K. B. Cease, H. Margalit, J. L. Spouge, J. A. Berzofsky, and C. DeLisi. 1987. Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J. Mol. Biol. 195:659.
48. Lee, K. H., D. Xie, E. Freire, and L. M. Amzel. 1994. Entropy changes in biological processes - side-chain entropy losses in folding and binding. Biophys. J. 66:AI3.
49. Baker, B. M., and K. P. Murphy. 1998. Prediction of binding energetics from structure using empirical parameterization. Methods Enzymol. 295:294.